Insulet Co. (PODD) Expected to Post Earnings of $0.07 Per Share

Analysts predict that Insulet Co. (NASDAQ:PODD) will report $0.07 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for Insulet’s earnings. The highest EPS estimate is $0.09 and the lowest is $0.03. Insulet reported earnings of ($0.12) per share in the same quarter last year, which indicates a positive year over year growth rate of 158.3%. The company is scheduled to announce its next quarterly earnings report on Wednesday, February 20th.

On average, analysts expect that Insulet will report full-year earnings of ($0.05) per share for the current fiscal year, with EPS estimates ranging from ($0.12) to ($0.02). For the next fiscal year, analysts expect that the company will post earnings of $0.39 per share, with EPS estimates ranging from $0.14 to $0.78. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Insulet.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.01. The business had revenue of $151.10 million during the quarter, compared to analyst estimates of $148.82 million. Insulet had a negative return on equity of 7.63% and a negative net margin of 2.54%. The company’s revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) EPS.

PODD has been the subject of a number of recent research reports. BidaskClub lowered Insulet from a “buy” rating to a “hold” rating in a research note on Wednesday, July 18th. Zacks Investment Research upgraded Insulet from a “hold” rating to a “strong-buy” rating and set a $101.00 price objective for the company in a research note on Tuesday, July 24th. Oppenheimer set a $96.00 price objective on Insulet and gave the company a “hold” rating in a research note on Friday, August 3rd. Jefferies Financial Group reiterated a “buy” rating and set a $97.00 price objective on shares of Insulet in a research note on Friday, August 3rd. Finally, Leerink Swann reiterated an “outperform” rating and set a $130.00 price objective on shares of Insulet in a research note on Tuesday, September 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $101.20.

In related news, insider Shacey Petrovic sold 1,134 shares of Insulet stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $86.91, for a total value of $98,555.94. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Aiman Abdel-Malek sold 602 shares of Insulet stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $88.58, for a total value of $53,325.16. The disclosure for this sale can be found here. Insiders have sold a total of 8,943 shares of company stock worth $803,215 over the last 90 days. Insiders own 3.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. SNS Financial Group LLC acquired a new stake in Insulet in the 3rd quarter worth about $225,000. CIBC Asset Management Inc purchased a new position in Insulet in the 3rd quarter worth approximately $227,000. Pier 88 Investment Partners LLC purchased a new position in Insulet in the 2nd quarter worth approximately $184,000. Harbour Capital Advisors LLC purchased a new position in Insulet in the 2nd quarter worth approximately $269,000. Finally, LPL Financial LLC purchased a new position in Insulet in the 1st quarter worth approximately $276,000.

Shares of NASDAQ PODD traded down $3.81 during trading on Friday, reaching $87.60. 536,402 shares of the company traded hands, compared to its average volume of 684,941. The firm has a market capitalization of $5.33 billion, a P/E ratio of -190.43 and a beta of 1.67. Insulet has a 12-month low of $66.57 and a 12-month high of $108.90. The company has a debt-to-equity ratio of 2.95, a quick ratio of 5.01 and a current ratio of 4.58.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Recommended Story: What are the most popular ETFs

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply